EANS-Adhoc: Sartorius AG
Preliminary Figures for the First Half of 2011
22.07.2011 – 21:11
-------------------------------------------------------------------------------- ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- 22.07.2011 Group sales revenue rises 12.2% to EUR353.7 million | Consolidated operating earnings soar 40.7% to EUR51.1 million; the respective margin improves to 14.4%| Management raises full-year guidance for sales revenue and profit In the first half of 2011, order intake for the Sartorius Group grew 13.6%currency-adjusted: +14.6%) from EUR336.4 million to EUR382.3 million. Sales revenue rose 12.2% (currency-adj.: +13.1%) to EUR353.8 million from EUR315.2 million in the previous year. The Biotechnology Division received orders valued at EUR257.2 million, up 16.2% (currency-adj.: +17.4%) from EUR221.4 million a year ago, and increased its sales revenue year on year by 9.7% (currency-adj.: +10.8%) to EUR229.4 million from EUR209.1 million. For the Mechatronics Division,order intake climbed 8.7% (currency-adj.: +9.2%) to EUR125.1 million from EUR115.1 million a year earlier; the division´s revenue grew 17.2% (currency-adj.: +17.6%) to EUR124.3 million from EUR106.1 million a year ago. Consolidated underlying EBITA surged from EUR36.3 million to EUR51.1 million; this reflects earnings before interest, taxes and amortization and is adjusted for extraordinary items of -EUR6.7 million (prev. yr.: -EUR1.9 mn). The respective margin jumped from 11.5% to 14.4%. The Biotechnology Division contributed an underlying EBITA of EUR38.6 million, up from EUR31.5 million a year ago, which means its margin increased from 15.0% to 16.8%. The Mechatronics Division more than doubled its contribution to earnings, from EUR4.8 million to EUR12.4 million; its earnings margin jumped from 4.5% to 10.0%. Excluding non-cash amortization, underlying net profit after minority interest for the first half totaled EUR24.0 million (prev. year: EUR15.9 mn); the respective earnings per share were at EUR1.41, up from EUR0.93 a year ago. Based on the Group's first-half figures, management has raised its 2011 full- year guidance for sales revenue and profit, and now projects that sales in constant currencies will grow for both divisions and thus also for the Group between 8% and 10% (former guidance: 6% to 8%). The underlying EBITA margin is forecasted to increase in constant currencies to between 17% and 18% for the Biotechnology Division (former guidance: about 17%) and to between 10% and 11% for the Mechatronics Division (former guidance: about 8%). Accordingly, the operating EBITA margin at Group level is expected to improve to between 14.5% and 15.5% (former guidance: about 14%). Moreover, management continues to anticipate that in 2011 operating cash flow will be significantly positive. Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, will discuss the results with analysts and investors on Monday, July 25, 2011, at 4:00 p.m. Central European Time in a webcast teleconference. You may dial into the teleconference starting at 3:45 p.m. CET at the following numbers: Germany +49 (0)69 2222 2244; France +33(0)1 70 99 42 73; UK +44(0)20 7136 2052; USA +1 212 444 0481. The dial-in code is as follows: 9817884 The webcast and presentation can be viewed at www.sartorius.com. Goettingen, July 22, 2011 ----------------------- Sartorius AG 37070 Goettingen, Germany Andreas Wiederhold Phone +49(0)551.308.1668 Fax +49(0)551.308.3153 andreas.wiederhold@ sartorius.com www.sartorius.com |Ad hoc Announcement |[pic] | Further inquiry note: Henriette Meyer Treasury & Investor Relations Tel.: +49 (0)551-308-3232 E-Mail: henriette.meyer@sartorius.com end of announcement euro adhoc -------------------------------------------------------------------------------- issuer: Sartorius AG Weender Landstr. 94-108 D-37075 Göttingen phone: +49 (0)551 308-0 FAX: +49 (0)551 308-3289 mail: info.investor@sartorius.com WWW: http://www.sartorius.com sector: Biotechnology ISIN: DE0007165607, DE0007165631 indexes: CDAX, Prime All Share, Technology All Share stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin, Hamburg, Stuttgart, Düsseldorf, Hannover, München language: English